Drugs / PG110
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00941746 | Aug 2009 → Jan 2011 | osteoarthritis, knee | Abbott | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PG110 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00941746 ↗ |
| Action | Inhibit | “a monoclonal antibody that inhibits the effects of the naturally occurring substance, nerve growth factor (NGF)” NCT00941746 ↗1“Beta-nerve growth factor inhibitor” CHEMBL2109526 ↗ |
| Modality | Monoclonal antibody | “PG110, a monoclonal antibody that inhibits” NCT00941746 ↗ |
| Route | Intravenous | “single intravenous dose of PG110” NCT00941746 ↗ |
| Target | NGF | “Beta-nerve growth factor inhibitor” CHEMBL2109526 ↗ |